OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Jun 29, 2023 • 14min
S9 Ep6: Short Shares Post-Conference Perspectives in Acute Lymphoblastic Leukemia From ASCO and EHA 2023
Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.
Jun 22, 2023 • 15min
S9 Ep5: Manana Discusses Systemic Racism in Oncology and Future Steps for Equitable Cancer Care
Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.
Jun 19, 2023 • 10min
S9 Ep4: Reuss Reviews the Development of LP-300 in Advanced NSCLC
Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.
Jun 15, 2023 • 12min
S9 Ep3: FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.
Jun 12, 2023 • 11min
S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
Jun 8, 2023 • 16min
S9 Ep1: Holowatyj Highlights Challenges and Opportunities in Appendix Cancer Research
Dr Holowatyj discusses symptoms associated with appendix cancer, challenges related to understanding the incidence and risk factors of this disease, and ongoing research regarding potential genetic links to this rare cancer.
Jun 5, 2023 • 18min
S8 Ep50: Raskin Reflects on the Career-Long Role of Fellowship and Education in Orthopaedic Oncology
Dr Raskin discusses the road from fellow to fellowship director at Massachusetts General Hospital, the importance of transparency in a program amid increasing emphasis on health and wellness, and the skills a successful program should impart on their trainees.
May 29, 2023 • 22min
S8 Ep49: Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML
Dr Andreeff discusses the evaluation of uproleselan for the treatment of patients with acute myeloid leukemia, the rationale for targeting E-selectin in patients with this disease, how uproleselan could amplify the effects of chemotherapy in the treatment of these patients.
May 25, 2023 • 24min
S8 Ep48: Gottschalk and Krenciute Discuss the Development of CAR T-cell Therapy in Pediatric Solid Tumors
Drs Gottschalk and Krenciute discuss the difficulties of translating successes with CAR T-cell therapy in adults to the pediatric population; ongoing research with investigational products that could reduce T-cell exhaustion, burnout, and the time from bench to bedside; and expectations for the future of cellular therapy in oncology.
May 22, 2023 • 14min
S8 Ep47: Mutale Discusses Disparities in Cancer Clinical Trial Eligibility, Access and Enrollment
Dr Mutale discusses common factors contributing to decreased access to cancer clinical trials, how trial enrollment criteria can affect which groups of patients are underrepresented in these trials, and steps that researchers and clinicians can take to increase diversity in clinical trials and mitigate these disparities.
